In the primary analysis of this phase II trial (NCT00496873), PCR was well tolerated and led to strong responses in previously-untreated iNHL patients. In this study, the follow-up results after a median of 108 months are reported. The primary endpoints of this study were progression-free survival (PFS) and overall survival (OS). The main secondary endpoint was the long-term safety profile of PCR in this patient population.

Clinical responses were assessed based on the Cheson criteria at baseline and after cycles 3, 6, and if needed 9. After treatment completion, responses were evaluated every three months in the first year, every six months in the second year and annually thereafter

Key results

Total patient cohort (n = 83)

Overall response rate (ORR): 92%

CR: 71% (n = 59)

Unconfirmed CR (CRu): 15.7% (n = 13)

Partial response (PR): 5% (n = 4)

CR/CRu were not significantly different among FL, MZL and SLL patient cohorts

Mar 15, 2019

Mar 13, 2019

Mar 1, 2019

Professional society

The European Lymphoma Institute is comprised of a network of top European specialists in the field of lymphoma who are dedicated to research, training and education. Together they look to define strategies to analyse and characterize lymphoma and its common diagnostic procedures and therapeutic standards, as well as to facilitate clinical and fundamental research. This all results in the advancement of lymphoma research and it guarantees equal access for all patients to the best possible care.